Combining biomarkers for prognostic modelling of Parkinson's disease.

ABSTRACT:

Background

Patients with Parkinson's disease (PD) have variable rates of progression. More accurate prediction of progression could improve selection for clinical trials. Although some variance in clinical progression can be predicted by age at onset and phenotype, we hypothesise that this can be further improved by blood biomarkers.

Objective

To determine if blood biomarkers (serum neurofilament light (NfL) and genetic status (glucocerebrosidase, GBA and apolipoprotein E (APOE))) are useful in addition to clinical measures for prognostic modelling in PD.

Methods

We evaluated the relationship between serum NfL and baseline and longitudinal clinical measures as well as patients' genetic (GBA and APOE) status. We classified patients as having

SUBMITTER: Vijiaratnam N 

PROVIDER: S-EPMC9279845 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature